Athira Pharma - שווי שוק בספרים ATHA

Athira Pharma, Inc. (ATHA) is developing innovative methods for neural connection regeneration to restore cognitive abilities in Alzheimer's disease. The funding for long-term development relies on existing cash reserves, with the current figure standing at 0.03. This price chart for the company's shares highlights a business model where substance synthesis and trials are outsourced to third-party contractors to reduce capital expenditures.

Book capitalization reflects the real value of net assets, demonstrating the efficiency of transforming operational processes into tangible shareholder capital. For Athira Pharma, Inc. (ATHA), whose humanitarian development of Alzheimer's drugs relies on stable US healthcare standards, analyzing the company's book capitalization on GURU.Markets allows for an assessment of the business's financial fundamental stability regardless of geopolitical volatility.